Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arctiin is a **natural lignan glycoside** isolated primarily from the seeds of *Arctium lappa* (burdock) and is a major active component of the medicinal herb known as Fructus Arctii[4][8]. It acts as a **prodrug** for arctigenin, meaning it is converted into the active form arctigenin in vivo[1][4]. Arctiin exhibits a variety of biological activities, including **anti-inflammatory, antioxidant, antiviral, and antiproliferative (anti-cancer) effects**[1][2][3][4][6][7][9]. Its mechanism of action is multifaceted and includes suppression of cyclin D1 protein expression, inhibition of inflammatory pathways (by reducing nitric oxide, prostaglandin E2, TNF-α, interleukin-1β, and IL-6), and antioxidant effects through activation of nuclear factor erythroid 2-related factor 2 (NRF2)[2][4][6][7]. Studies have shown efficacy in models of metabolic disorders, osteoarthritis, neuroprotection, and various cancers, though most human data are preclinical[1][2][4][6][7]. Arctiin is also reported to have anti-osteoporotic and anti-diabetic potential[2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on arctiin.